Bluejay Diagnostics, Inc. Noninterest Expense Investment Advisory Fees
Bluejay Diagnostics, Inc. (BJDX) reported Noninterest Expense Investment Advisory Fees of $384.67 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:NoninterestExpenseInvestmentAdvisoryFees · last filed 2026-08-12
- Bluejay Diagnostics, Inc. noninterest expense investment advisory fees for the quarter ending 2025-06-30 was -$330.00.
- Bluejay Diagnostics, Inc. noninterest expense investment advisory fees for the quarter ending 2025-03-31 was $385.00K.
| Period end | Noninterest Expense Investment Advisory Fees | Noninterest Expense Investment Advisory Fees 3 month | Noninterest Expense Investment Advisory Fees 6 month |
|---|---|---|---|
| 2025-06-30 | -$330.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $384.67K 10-Q · filed 2025-08-07 | |
| 2025-04-07 | $384.67K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $385.00K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |